COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Group A, in addition to standard treatment, receives oral ivermectin 200 micrograms per kilogram of body weight for the first and third days of treatment. Standard
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Laboratory confirmation of COVID-19 virus by RT-PCR or imaging findings consistent with COVID-19 Severe disease (respiratory rate more than 30 per minute, oxygen saturation less than 94%, or pulmonary infiltration more than 50% in both lungs) Age above 18 years Willingness to participate in this study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: 5th day of hospitalization. Method of measurement: Patient medical record.;Intubation requirement. Timepoint: 5th day of hospitalization. Method of measurement: Patient medical record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Oxygen saturation. Timepoint: First and fifth days of hospitalization. Method of measurement: Pulse oximeter.;Respiratory rate. Timepoint: First and fifth days of hospitalization. Method of measurement: Physical examination by physician.;Serum CRP level. Timepoint: First and fifth days of hospitalization. Method of measurement: Laboratory report.;Lymphocyte count. Timepoint: First and fifth days of hospitalization. Method of measurement: Laboratory report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirreza Keyvanfar
Shahid Beheshti University of Medical Sciences
Outcome results
None listed